Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
18.37
+0.08 (0.44%)
At close: Jul 29, 2026, 4:00 PM EDT
18.37
0.00 (0.00%)
After-hours: Jul 29, 2026, 4:10 PM EDT
Relay Therapeutics Employees
Relay Therapeutics had 193 employees as of March 31, 2026. The number of employees decreased by 66 or -25.48% compared to the same quarter last year.
Employees
193
Change
-66
Growth
-25.48%
Revenue / Employee
$55,316
Profits / Employee
-$1,412,979
Market Cap
4.00B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 193 | -66 | -25.48% |
| Dec 31, 2025 | 192 | -69 | -26.44% |
| Sep 30, 2025 | 188 | -106 | -36.05% |
| Jun 30, 2025 | 197 | -107 | -35.20% |
| Mar 31, 2025 | 259 | -50 | -16.18% |
| Dec 31, 2024 | 261 | -62 | -19.20% |
| Sep 30, 2024 | 294 | -49 | -14.29% |
| Jun 30, 2024 | 304 | -41 | -11.88% |
| Mar 31, 2024 | 309 | -19 | -5.79% |
| Dec 31, 2023 | 323 | -4 | -1.22% |
| Sep 30, 2023 | 343 | 23 | 7.19% |
| Jun 30, 2023 | 345 | 40 | 13.11% |
| Mar 31, 2023 | 328 | 52 | 18.84% |
| Dec 31, 2022 | 327 | 82 | 33.47% |
| Sep 30, 2022 | 320 | 88 | 37.93% |
| Jun 30, 2022 | 305 | 102 | 50.25% |
| Mar 31, 2022 | 276 | 113 | 69.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| ACADIA Pharmaceuticals | 798 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Celcuity | 155 |
| Edgewise Therapeutics | 154 |
| Parabilis Medicines | 145 |
RLAY News
- 8 days ago - Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs - TheFly
- 13 days ago - Relay Therapeutics initiated with a Buy at Canaccord on zovegalisib’s potential - TheFly
- 13 days ago - Relay Therapeutics initiated with a Buy at Canaccord - TheFly
- 21 days ago - Relay Therapeutics initiated with an Overweight at JPMorgan - TheFly
- 7 weeks ago - Relay Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Relay Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - GlobeNewsWire
- 2 months ago - Relay Therapeutics price target raised to $26 from $22 at Guggenheim - TheFly